Neurofibromatosis Research Grants
CS/HB 497 creates the Neurofibromatosis Disease Grant Program within the Florida Department of Health. The program’s purpose is to speed research toward diagnostics, treatments, and cures for neurofibromatosis by awarding competitive, peer-reviewed grants for scientific and clinical research. Eligible applicants include universities and established research institutes in Florida, and qualified investigators may compete regardless of institutional affiliation.
The bill allows the department, after consulting the Rare Disease Advisory Council, to fund investigator-initiated, institutional, and collaborative research proposals. It directs the department to use independent peer review panels to score applications based on scientific merit, with an emphasis on objectivity, consistency, and high-quality review. The bill also permits preference for collaborative proposals that bring together institutions, researchers, and community practitioners.
The bill further establishes conflict-of-interest safeguards for both the advisory council and peer review panels. Members are barred from participating in discussions or decisions involving proposals from entities with which they have governance, employment, or contractual ties. In addition, any unspent General Revenue appropriations for the program that are obligated or committed by the end of the fiscal year may be carried forward for up to five years.
The bill’s impact on state law is to add a new statutory section, s. 381.994, F.S., and create a dedicated state grant program for neurofibromatosis research within the Department of Health. It does not create a new entitlement or mandate ongoing funding; rather, it operates subject to legislative appropriation and establishes the framework for how state research dollars would be awarded and administered. The bill takes effect July 1, 2026.
The available voting history suggests broad support, with the House Health Professions & Programs Subcommittee approving the bill 13-0. No committee transcript was provided, so there is little direct evidence of opposition in the record supplied. The main policy issues reflected in the text are not about whether to support research, but about ensuring fair peer review, avoiding conflicts of interest, and directing limited state funds toward scientifically meritorious projects.
This bill creates a new section of Florida Statutes establishing the Neurofibromatosis Disease Grant Program in the Department of Health. It authorizes the state to award competitive research grants for neurofibromatosis, subject to appropriation, and sets rules for eligibility, peer review, advisory council involvement, conflict-of-interest restrictions, and carryforward of certain unspent funds. The measure primarily affects the Department of Health, Florida universities and research institutes, and investigators seeking state research funding.
The bill appears to have been received positively, at least in the committee vote provided, where it passed unanimously 13-0 in the House Health Professions & Programs Subcommittee. The text and available context suggest a generally supportive posture toward funding rare disease research and improving treatment options for neurofibromatosis. No opposing testimony or recorded controversy was provided in the materials supplied.
There is little visible contention in the available record. The bill’s main points of policy attention are procedural: how grant applications are reviewed, how the Rare Disease Advisory Council and peer review panels avoid conflicts of interest, and whether collaborative proposals should receive preference. Any potential disagreement would likely center on funding priorities, the use of state appropriations for a disease-specific program, and the fairness and transparency of the peer-review process.